Uncategorized

Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure

Published

3 weeks ago

on

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version